Related Experiment Videos
Intraperitoneal chemotherapy: the use of concurrent systemic neutralizing agents.
Seminars in Oncology
|September 1, 1985
Summary
Intraperitoneal chemotherapy for ovarian cancer shows promise. Systemic agents like leucovorin and thiosulfate can enhance drug exposure and reduce toxicity, paving the way for Phase II trials.
Area of Science:
- Oncology
- Pharmacology
Background:
- Intraperitoneal chemotherapy offers significant advantages for treating human ovarian carcinoma.
- Systemic neutralizing agents can potentially improve the therapeutic index of intraperitoneal treatments.
Purpose of the Study:
- To explore the use of systemic neutralizing agents to enhance the efficacy and safety of intraperitoneal chemotherapy for ovarian cancer.
- To evaluate the potential of leucovorin and thiosulfate in combination with intraperitoneal agents.
Main Methods:
- Investigated the pharmacologic principles of combining intraperitoneal chemotherapy with systemic administration of neutralizing agents.
- Focused on methotrexate and cisplatin as model agents for intraperitoneal administration.
Main Results:
- Systemic leucovorin allows for prolonged exposure to intraperitoneal methotrexate.
- Systemic thiosulfate offers kidney protection against cisplatin, enabling increased cisplatin exposure.
Conclusions:
- The combination of intraperitoneal chemotherapy with specific systemic neutralizing agents presents a promising strategy for ovarian cancer treatment.
- These enhanced therapeutic approaches are ready for advancement into Phase II clinical trials.